Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo-controlled trial (CAPTIVATE)

By sjmartinez • February 7, 2023

Chang L, Cash BD, Lembo A, Kunkel DC, English BA, Lindstrom B, Gu G, Skare S, Gilder K, Turner S, Cataldi F, Lipkis D, Jan T. Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo-controlled trial (CAPTIVATE). Neurogastroenterol Motil. 2023 Feb 5:e14539. doi: 10.1111/nmo.14539. Epub ahead of print. PMID: 36740814.

Tags: abdominal pain, cannabinoid receptor agonists, cannabinoids, Digestive Diseases, Irritable Bowel Syndrome, olorinab, Publications

Reprogramming of cholesterol sensing in epithelial cells supports pancreatic inflammation

Milan G, Mareninova OA, Fantuz M, Spacci M, Paoli C, Pineda JA, Noè R, Calciolari B, Zoncu R, Gukovskaya AS, Carrer A. Reprogramming of cholesterol[...]

Recommendations for recognizing and diagnosing Acute Hepatic Porphyria in atypical patient populations

Schmolly K, Rudrapatna V, Beaven S. Recommendations for recognizing and diagnosing Acute Hepatic Porphyria in atypical patient populations. Orphanet J Rare Dis. 2025 Oct 24;20(1):539.[...]

High concentrations of L-lysine cause mitochondrial damage and necrosis in isolated pancreatic acinar cells

Végh ET, Balla Z, Dágó Á, Salamah O, Tóth B, Elperin J, Speakman S, Shalbueva N, Pallagi P, Rázga Z, Kiss L, Gukovskaya A, Rakonczay[...]